Illumina, Inc. (ILMN) KPIs and segments
Close on Nov 18, 2026Market cap $31.75BP/E 36.0Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Illumina · năm tài chính kết thúc ngày 28 tháng 12
Nhìn nhanh KPI của Illumina: 36 chỉ số vận hành, trong đó có Remaining Performance Obligations, Total Contract Liabilities — Deferred Revenue và High-Throughput Sequencing Volume Share on NovaSeq X, lấy từ 158 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Core Illumina($M) | 1,129 | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,092 | 1,056 | 1,097 | |
Sequencing($M)3 | 1,021 | 1,054 | 995 | 1,066 | 1,001 | 972 | 947 | 1,004 | 995 | 1,016 | 979 | 1,024 | |
Consumables($M) | 764 | 775 | 726 | 756 | 747 | 740 | 696 | 698 | 741 | 729 | 691 | 682 | |
Service($M) | 155 | 154 | 151 | 156 | 147 | 136 | 142 | 152 | 150 | 171 | 178 | 181 | |
Instruments($M) | 102 | 125 | 118 | 154 | 107 | 96 | 109 | 154 | 104 | 116 | 110 | 161 | |
Microarray($M)3 | 108 | 105 | 96 | 93 | 83 | 87 | 94 | 100 | 85 | 96 | 97 | 98 | |
Consumables($M) | 77 | 77 | 71 | 76 | 69 | 71 | 72 | 81 | 66 | 78 | 71 | 74 | |
Service($M) | 28 | 23 | 23 | 13 | 10 | 11 | 19 | 14 | 16 | 14 | 22 | 18 | |
Instruments($M) | 3 | 5 | 2 | 4 | 4 | 5 | 3 | 5 | 3 | 4 | 4 | 6 | |
GRAIL($M) | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 27 | 31 | ||||
Consumables($M) | 841 | 852 | 797 | 832 | 816 | 811 | 768 | 779 | 807 | 807 | 762 | 756 | |
Service($M) | 183 | 177 | 174 | 169 | 157 | 147 | 161 | 166 | 166 | 185 | 200 | 199 | |
Instruments($M) | 105 | 130 | 120 | 158 | 111 | 101 | 112 | 159 | 107 | 120 | 114 | 167 | |
Americas($M) | 638 | 612 | 586 | 570 | 589 | 609 | 640 | 603 | 601 | ||||
United States and Canada($M) | 637 | 653 | 590 | 596 | 569 | 555 | |||||||
Europe($M) | 353 | 309 | 310 | 293 | 326 | 291 | 289 | 279 | 315 | ||||
Europe, Middle East, Africa and Latin America($M) | 347 | 368 | 356 | 354 | 355 | 332 | |||||||
Asia-Pacific, Middle East and Africa($M) | 112 | 111 | 100 | 106 | 109 | 105 | 108 | 116 | 124 | ||||
Asia-Pacific($M) | 86 | 82 | 93 | 82 | 72 | 82 | |||||||
China($M) | 59 | 56 | 52 | 56 | 52 | 63 | 72 | 80 | 75 | 75 | 78 | 82 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)2 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1 | |||||||||||||
Remaining performance obligations (RPO)($M) | 933 | 1,000 | 1,100 | 747 | 862 | 891 | 688 | 717 | 796 | ||||
Remaining Performance Obligations — Product & Instrument Service Backlog ($M)($M)3 | 933 | 1,000 | 1,100 | 738 | 747 | 862 | 891 | 657 | 688 | 717 | 796 | 653 | |
RPO Expected to Convert to Revenue Within 12 Months (%)(%) | 76.0% | 83.0% | 85.0% | 77.0% | 77.0% | 79.0% | 83.0% | 78.0% | 82.0% | 82.0% | 87.0% | 82.0% | |
RPO Expected to Convert to Revenue in 13–24 Months (%)(%) | 14.0% | 11.0% | 9.0% | 13.0% | 11.0% | 10.0% | 7.0% | 10.0% | 13.0% | 13.0% | 9.0% | 13.0% | |
Development and Licensing Remaining Performance Obligations ($M)($M) | 33 | 43 | 38 | ||||||||||
Total Contract Liabilities — Deferred Revenue ($M)($M)3 | 319 | 333 | 344 | 346 | 307 | 324 | 329 | 327 | 293 | 305 | 324 | 329 | |
Current Contract Liabilities — Short-Term Deferred Revenue ($M)($M) | 250 | 261 | 269 | 270 | 234 | 247 | 256 | 260 | 235 | 238 | 248 | 252 | |
Revenue Recognized from Beginning Contract Liability Balance ($M)($M) | 47 | 71 | 98 | 30 | 47 | 70 | 97 | 48 | 70 | 95 | 39 | ||
Contract Assets, Net ($M)($M) | 20 | 20 | 23 | 21 | 22 | 15 | 15 | 16 | 16 | 16 | 15 | 18 | |
High-Throughput Sequencing Volume Share on NovaSeq X Platform (%)(%)5 | 84.0% | 83.0% | 82.0% | 69.0% | |||||||||
High-Throughput Consumables Revenue Share on NovaSeq X Platform (%)(%) | 60.0% | 59.0% | 55.0% | 55.0% | 44.0% | ||||||||
Research & Applied High-Throughput Volume Share on NovaSeq X (%)(%) | 90.0% | 90.0% | 90.0% | 90.0% | |||||||||
Clinical High-Throughput Volume Share on NovaSeq X (%)(%) | 78.0% | 78.0% | 76.0% | 55.0% | |||||||||
Clinical Sequencing Consumables Revenue Growth YoY, Rest of World Ex-China (%)(%) | 14.0% | 15.0% | 20.0% | 20.0% | |||||||||
Research & Applied Sequencing Consumables Revenue Growth YoY, Rest of World Ex-China (%)(%) | -6.0% | -7.0% | -12.0% | ||||||||||
Rest-of-World (Ex-Greater China) Organic Revenue Growth YoY (%)(%)5 | 4.7% | 8.1% | 3.5% | ||||||||||
Consolidated Organic Revenue Growth YoY (%)(%) | 4.8% | 6.5% | 1.2% | ||||||||||
Reported Consolidated GAAP Revenue Growth YoY (%)(%) | 4.2% | 9.5% | 4.8% | ||||||||||
Revenue Growth Impact from Acquisitions YoY (%)(%) | -2.4% | -2.1% | -1.7% | ||||||||||
Revenue Growth Impact from Foreign Currency Exchange Rates YoY (%)(%) | -0.4% | -0.9% | -1.9% | ||||||||||
Revenue Growth Offset from Greater China Exclusion YoY (%)(%) | -0.1% | 1.6% | 2.3% | ||||||||||
Total Disaggregated Revenue by Source ($M)($M)3 | 1,129 | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,112 | 1,076 | 1,122 | |
Total Sequencing Revenue ($M)($M)1 | 1,021 | 1,054 | 995 | 1,066 | 1,001 | 972 | 947 | 1,004 | 995 | 1,016 | 979 | 1,024 | |
Sequencing Product Revenue ($M)($M) | 866 | 900 | 844 | 910 | 854 | 836 | 805 | 852 | 845 | 845 | 801 | 843 | |
Total Microarray Revenue ($M)($M)1 | 108 | 105 | 96 | 93 | 83 | 87 | 94 | 100 | 85 | 96 | 97 | 98 | |
Microarray Product Revenue ($M)($M) | 80 | 82 | 73 | 80 | 73 | 76 | 75 | 86 | 69 | 82 | 75 | 80 | |
Total Consolidated Product Revenue ($M)($M) | 946 | 982 | 917 | 990 | 927 | 912 | 880 | 938 | 914 | 927 | 876 | 923 | |
Unaudited Pro Forma Combined Revenue Including SomaLogic ($M)($M)1 | 1,129 | 1,159 | 1,099 | 1,108 | 1,076 | 1,060 | |||||||
Unaudited Pro Forma Combined Net Income Including SomaLogic ($M)($M) | 218 | 192 | 141 | 140 | 241 | 76 | |||||||
Selling and Marketing Expense ($M)($M) | 159 | 164 | 158 | 160 | 148 | 146 | 165 | 158 | 163 | 165 | 153 | ||
General and Administrative Expense ($M)($M) | 122 | 109 | 114 | 149 | 129 | 88 | 102 | 121 | 76 | -105 | 183 | ||
Total Share-Based Compensation Expense Before Taxes ($M)($M)8 | 75 | 72 | 60 | 63 | 70 | 69 | 73 | 80 | 84 | 110 | 96 | 94 | |
Share-Based Compensation — Cost of Product Revenue ($M)($M) | 4 | 5 | 4 | 4 | 5 | 6 | 5 | 6 | 7 | 7 | 5 | 7 | |
Share-Based Compensation — Cost of Service and Other Revenue ($M)($M) | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |
Share-Based Compensation — Research and Development ($M)($M) | 25 | 26 | 24 | 23 | 26 | 28 | 30 | 31 | 33 | 43 | 39 | 38 | |
Share-Based Compensation — Selling, General and Administrative ($M)($M) | 45 | 41 | 31 | 35 | 38 | 34 | 37 | 42 | 43 | 59 | 50 | 47 | |
Share-Based Compensation Related Income Tax Benefits ($M)($M) | 17 | 16 | 13 | 15 | 15 | 15 | 16 | 17 | 18 | 26 | 22 | 22 | |
Share-Based Compensation Expense, Net of Taxes ($M)($M) | 58 | 56 | 47 | 48 | 55 | 54 | 57 | 63 | 66 | 84 | 74 | 72 | |
Unrecognized Share-Based Compensation Cost ($M)($M) | 442 | 494 | 576 | 391 | 462 | 553 | 687 | 565 | 655 | 735 | 834 | 496 | |
Weighted-Average Recognition Period for Unrecognized Share-Based Compensation (Years)(năm) | 2.0 | 2.3 | 2.5 | 2.3 | 2.3 | 2.5 | 2.7 | 2.5 | 2.5 | ||||
Total Current Inventories, Net ($M)($M)6 | 667 | 629 | 611 | 564 | 590 | 575 | 537 | 547 | 574 | 561 | 584 | 587 | |
Raw Materials Inventory ($M)($M) | 319 | 295 | 268 | 254 | 251 | 227 | 216 | 225 | 238 | 232 | 262 | 276 | |
Work in Process (WIP) Inventory ($M)($M) | 434 | 426 | 427 | 398 | 418 | 419 | 404 | 404 | 419 | 416 | 405 | 402 | |
Finished Goods Inventory ($M)($M) | 58 | 57 | 55 | 45 | 50 | 47 | 26 | 31 | 37 | 35 | 35 | 30 | |
Total Gross Inventory Before Reserves ($M)($M) | 811 | 778 | 750 | 697 | 719 | 693 | 646 | 660 | 694 | 683 | 702 | 708 | |
Inventory Valuation and Obsolescence Reserves ($M)($M) | 119 | 123 | 119 | 133 | 129 | 118 | 109 | 113 | 120 | 122 | 118 | 121 | |
Non-Current Work in Process Inventory ($M)($M) | 25 | 26 | 20 | 0 | |||||||||
Reserve for Product Warranties — Ending Balance ($M)($M)2 | 14 | 17 | 16 | 17 | 14 | 16 | 17 | 18 | 16 | 17 | 20 | 21 | |
Product Warranty Reserve — Additions Charged to Cost of Product Revenue ($M)($M) | 4 | 6 | 6 | 11 | 3 | 6 | 8 | 12 | 8 | 10 | 12 | 12 | |
Product Warranty Reserve — Repairs and Replacements Deductions ($M)($M) | 7 | 5 | 7 | 8 | 5 | 7 | 9 | 10 | 9 | 13 | 13 | 10 | |
Total Government Assistance Grants Receivable ($M)($M)1 | 56 | 45 | 24 | 21 | |||||||||
Current Government Assistance Grants Receivable ($M)($M) | 15 | 18 | 3 | 8 | |||||||||
Common Shares Repurchased Under Authorized Programs (Thousand Shares)5 | 47 | 942 | 2,005 | 337 | 1,236 | 4,489 | 1,728 | 134 | 770 | ||||
Total Cost of Common Shares Repurchased ($M)($M) | 9 | 123 | 243 | 42 | 121 | 384 | 201 | 17 | 99 | ||||
Weighted-Average Price Paid per Repurchased Share ($/Share)($) | 191 | 129 | 121 | 124 | 97.10 | 84.66 | 116 | 129 | 128 | ||||
Remaining Share Repurchase Authorization ($M)($M) | 1,770 | 1,779 | 400 | 643 | 684 | 804 | 1,184 | 1,384 | 1,402 | ||||
Cash Paid for Common Stock Repurchases ($M)($M) | 9 | 128 | 242 | 42 | 130 | 370 | 200 | 17 | 99 | 0 | 0 | 0 | |
Treasury Stock Carrying Value ($M)($M) | 5,065 | 5,054 | 4,931 | 4,699 | 4,645 | 4,523 | 4,139 | 3,934 | 3,893 | 3,794 | 3,793 | 3,792 | |
Non-GAAP Gross Profit ($M)($M)5 | 850 | 790 | 744 | 2,964 | 750 | 735 | 702 | 2,973 | 2,228 | 1,466 | 708 | ||
Non-GAAP Gross Margin (%)(%) | 75.3% | 68.2% | 68.2% | 68.2% | 69.2% | 69.4% | 67.4% | 68.6% | 69.0% | 68.3% | 67.1% | ||
Non-GAAP Operating Profit ($M)($M) | 325 | 260 | 239 | 275 | 265 | 252 | 212 | 218 | 244 | ||||
Non-GAAP Operating Margin (%)(%) | 28.8% | 22.5% | 21.9% | 23.7% | 24.5% | 23.8% | 20.4% | 19.7% | 22.6% | ||||
Non-GAAP Diluted Earnings per Share ($/Share)($) | 1.62 | 1.31 | 1.15 | 1.35 | 1.34 | 1.19 | 0.97 | 0.95 | 1.14 | 1.09 | 0.98 | ||
Free Cash Flow — Form 8-K Reconciliation ($M)($M) | 378 | 162 | 251 | 267 | 253 | 204 | 208 | 322 | 284 | 48 | 41 | 173 | |
GRAIL Total Revenue ($M)($M)6 | 37.5 | 44.7 | 40.8 | 36.2 | 35.5 | 31.8 | |||||||
GRAIL Galleri Multi-Cancer Early Detection Screening Revenue ($M)($M)2 | 37.3 | 42.6 | 39.8 | 32.8 | 34.4 | 29.1 | |||||||
Galleri Screening Test Sales Volume Growth YoY (%)(%) | 24.0% | 35.0% | 50.0% | ||||||||||
Galleri Screening Test Average Selling Price (ASP) Change YoY (%)(%) | -9.0% | -8.0% | -9.0% | ||||||||||
GRAIL Development Services Revenue ($M)($M) | 0.27 | 2.04 | 0.95 | 3.39 | 1.17 | 2.70 | |||||||
GRAIL Cost of Screening Revenue — Exclusive of Amortization ($M)($M) | 22.0 | 23.4 | 21.2 | 15.9 | 19.4 | 17.1 | |||||||
GRAIL Research and Development Expense ($M)($M) | 44.1 | 47.4 | 48.0 | 48.7 | 46.6 | 53.6 | |||||||
GRAIL Sales and Marketing Expense ($M)($M) | 41.7 | 37.7 | 30.7 | 25.5 | 28.5 | 35.0 | |||||||
GRAIL General and Administrative Expense ($M)($M) | 40.7 | 50.7 | 42.8 | 37.4 | 37.9 | 45.1 | |||||||
Illumina Premarket Approval (PMA) Original & Supplement Approvals (Approvals)2 | 2 | 2 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | |
Illumina Medical Device Enforcement Recall Events (Events) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Illumina MAUDE Medical Device Adverse Event Reports (Reports) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
U.S. Industry-Wide 510(k) Medical Device Clearances (Clearances)2 | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
U.S. Industry-Wide PMA Medical Device Approvals (Approvals) | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
U.S. Industry-Wide MAUDE Medical Device Adverse Event Reports (Reports) | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
U.S. PPI — Analytical Laboratory Instruments (WPU118501, Index 1985=100)(×)3 | 203.64 | 203.64 | 202.01 | 197.85 | 195.85 | 195.49 | 195.29 | 191.73 | 191.56 | 191.72 | 190.66 | 186.75 | |
U.S. PPI — In-Vitro Diagnostic Substance Manufacturing (PCU325413325413, Index)(×) | 300.64 | 302.78 | 304.31 | 300.43 | 298.72 | 297.45 | 292.10 | 284.59 | 284.49 | 284.62 | 285.08 | 283.01 | |
U.S. PPI — Medical and Diagnostic Laboratories (PCU621511621511, Index)(×) | 101.50 | 101.52 | 101.38 | 101.29 | 101.29 | 101.26 | 101.17 | 100.87 | 100.91 | 100.97 | 100.79 | 100.86 | |
U.S. PPI — Surgical and Medical Instrument Manufacturing (PCU339112339112, Index)(×) | 163.38 | 162.89 | 161.74 | 159.58 | 157.80 | 156.88 | 157.06 | 155.15 | 154.40 | 154.13 | 153.62 | 151.03 | |
Consolidated Revenue ($M)($M)15 | 1,129 | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,112 | 1,076 | 1,122 | |
Cost of Revenue ($M)($M) | 299 | 389 | 370 | 400 | 351 | 364 | 358 | 376 | 335 | 391 | 409 | 448 | |
Gross Profit ($M)($M) | 830 | 770 | 721 | 759 | 733 | 695 | 683 | 728 | 745 | 721 | 667 | 674 | |
Research and Development Expense ($M)($M) | 244 | 252 | 240 | 239 | 229 | 247 | 252 | 256 | 253 | 325 | 339 | 341 | |
Selling, General and Administrative Expense ($M)($M) | 281 | 273 | 272 | 309 | 277 | 234 | 267 | 279 | 239 | 147 | 439 | 485 | |
Total Operating Expenses ($M)($M) | 525 | 525 | 512 | 558 | 506 | 481 | 519 | 553 | 4 | 2,358 | 778 | 838 | |
Operating Income ($M)($M) | 305 | 245 | 209 | 201 | 227 | 214 | 164 | 175 | 741 | -1,637 | -111 | -164 | |
Interest Income ($M)($M) | 12 | 8 | 11 | 10 | 9 | 10 | 11 | 10 | 11 | 13 | 12 | 11 | |
Interest Expense ($M)($M) | 24 | 24 | 24 | 26 | 25 | 25 | 25 | 25 | 36 | 20 | 18 | 18 | |
Income Before Income Taxes ($M)($M) | 264 | 260 | 157 | 377 | 220 | 306 | 182 | 187 | 720 | -1,976 | -109 | -167 | |
Provision for Income Taxes ($M)($M) | 44 | 53 | 23 | 43 | 70 | 71 | 51 | 0 | 15 | 12 | 17 | 8 | |
Consolidated Net Income ($M)($M) | 220 | 207 | 134 | 334 | 150 | 235 | 131 | 186 | 705 | -1,988 | -126 | -176 | |
Basic Earnings per Share ($/Share)($) | 1.46 | 1.37 | 0.88 | 0.98 | 1.49 | 0.83 | 4.43 | -12.48 | -0.79 | ||||
Diluted Earnings per Share ($/Share)($) | 1.43 | 1.35 | 0.87 | 0.98 | 1.49 | 0.82 | 4.42 | -12.48 | -0.79 | ||||
Weighted-Average Basic Shares Outstanding (Million Shares)(M) | 151 | 151 | 153 | 153 | 157 | 159 | 159 | 159 | 159 | ||||
Weighted-Average Diluted Shares Outstanding (Million Shares)(M) | 154 | 153 | 154 | 154 | 157 | 159 | 160 | 159 | 159 | ||||
Total Assets ($M)($M)12 | 6,812 | 6,650 | 6,559 | 6,644 | 6,177 | 6,087 | 6,182 | 6,303 | 6,014 | 6,081 | 10,040 | 10,111 | |
Cash and Cash Equivalents ($M)($M) | 1,289 | 1,040 | 1,089 | 1,418 | 1,050 | 934 | 1,113 | 1,127 | 869 | 920 | 1,108 | 1,048 | |
Short-Term Investments ($M)($M) | 48 | 128 | 66 | 215 | 228 | 221 | 124 | 93 | 70 | 74 | 6 | ||
Accounts Receivable, Net ($M)($M) | 738 | 764 | 738 | 854 | 729 | 701 | 699 | 735 | 699 | 641 | 635 | 734 | |
Inventories, Net ($M)($M) | 667 | 629 | 611 | 564 | 590 | 575 | 537 | 547 | 574 | 561 | 584 | 587 | |
Property, Plant and Equipment, Net ($M)($M) | 731 | 745 | 755 | 759 | 748 | 764 | 782 | 815 | 832 | 859 | 964 | 1,007 | |
Operating Lease Right-of-Use Assets ($M)($M) | 356 | 362 | 371 | 370 | 382 | 397 | 410 | 419 | 453 | 460 | 550 | 544 | |
Goodwill ($M)($M) | 1,284 | 1,284 | 1,284 | 1,113 | 1,113 | 1,113 | 1,113 | 1,113 | 1,113 | 1,079 | 2,545 | 2,545 | |
Intangible Assets, Net ($M)($M) | 391 | 410 | 430 | 210 | 225 | 238 | 278 | 295 | 305 | 278 | 2,940 | 2,993 | |
Accounts Payable ($M)($M) | 241 | 230 | 218 | 240 | 218 | 200 | 207 | 221 | 191 | 199 | 201 | 245 | |
Accrued Liabilities ($M)($M) | 915 | 848 | 849 | 846 | 746 | 762 | 734 | 827 | 784 | 1,265 | 1,273 | 1,325 | |
Long-Term Debt ($M)($M) | 1,789 | 1,491 | 1,490 | 1,490 | 994 | 1,492 | 1,491 | 1,490 | 1,988 | 1,490 | 1,490 | 1,489 | |
Total Stockholders' Equity ($M)($M) | 3,145 | 2,838 | 2,676 | 2,723 | 2,381 | 2,258 | 2,368 | 2,373 | 2,125 | 1,436 | 5,734 | 5,745 | |
Operating Cash Flow ($M)($M)2 | 419 | 201 | 289 | 321 | 284 | 234 | 240 | 364 | 316 | 80 | 77 | 224 | |
Capital Expenditures ($M)($M) | 40 | 40 | 38 | 55 | 31 | 30 | 32 | 29 | 32 | 31 | 36 | 51 | |
Stock-Based Compensation — Cash Flow Statement ($M)($M) | 75 | 72 | 60 | 63 | 70 | 69 | 73 | 79 | 84 | 110 | 96 | 94 | |
Core Illumina Segment Revenue — Through Q2 2026 ($M)($M)1 | 1,159 | 1,091 | 1,159 | 1,084 | 1,059 | 1,041 | 1,104 | 1,080 | 1,092 | 1,056 | 1,097 | ||
Total Product Revenue — Product Series Through Q2 2026 ($M)($M) | 982 | 917 | 990 | 927 | 912 | 880 | 938 | 914 | 927 | 876 | 923 | ||
15 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Remaining Performance Obligations (RPO / Backlog) in Group 1 represent the aggregate transaction price allocated to unsatisfied or partially unsatisfied performance obligations for product and instrument service contracts as disclosed in Note 2 of Form 10-K and Form 10-Q ($933.0 million as of Q3 2026, with 76% expected to convert to revenue within 12 months and 14% in months 13–24, plus $33.0 million of Development and Licensing RPO).
- Period-splitting formulas: Quarterly flow series reported on a three-month (Q1–Q3), six-month (6M), and nine-month (9M) basis in Form 10-Q and on a full-year basis in Form 10-K (Note 2 Revenue by Source matrix, Greater China & legacy regional revenues, ASU 2023-07 Selling & Marketing and General & Administrative expenses, Share-Based Compensation by function, Product Warranty additions and repairs, and Cash Flow statement items) derive fourth-quarter values via Q4 = full year (10-K) − nine months (10-Q) from the same reporting basis.
- Consolidated vs. parent-only financial statements: Illumina prepares consolidated financial statements in accordance with U.S. GAAP and does not file standalone parent-only financial statements (Schedule I is not required). Following the June 24, 2024 spin-off of GRAIL, Inc. (in which Illumina retains a 14.5% equity stake), GRAIL's standalone revenue, Galleri test volume/ASP growth rates, and operating expenses are presented in Group 5 from GRAIL's Form 10-Q filings.
- Commercial region realignment in Q1 2026: Beginning in Q1 2026, Illumina reorganized its global commercial structure into four regions — United States and Canada (USCAN), Europe, Middle East, Africa and Latin America (EMEALA), Greater China, and Asia-Pacific (APAC) — with comparative 2025 periods restated. Legacy regional series (Americas, Europe, and APMEA) are preserved through their structural break at FY2025Q4.
Không hiện vì thiếu các kỳ gần đây (9)
- High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Exact Quarterly NovaSeq X Instrument Shipments (Units — Point Disclosures Only)
- High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Cumulative Active NovaSeq X Installed Base (Instruments — Point Disclosures Only)
- High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Share of Quarterly NovaSeq X Placements to Clinical Customers (%)
- High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Clinical End-Market Share of Total Sequencing Consumables Revenue (%)
- Rest-of-World (Ex-Greater China) Organic Revenue Growth YoY (%) › Revenue Growth Impact from Customer IEEPA Tariff Refunds YoY (% — Q3 2026 Only)
- Total Government Assistance Grants Receivable ($M) › Government Incentive Benefits Recognized in Operating Income ($M)
- Global Workforce — Total Employees (Employees) › Issued U.S. Patents Owned or Exclusively Licensed (Patents — Discontinued After FY2022)
- Global Workforce — Total Employees (Employees) › Pending U.S. Patent Applications (Applications — Discontinued After FY2022)
- Global Workforce — Total Employees (Employees) › Women Share of Global Workforce — Form 10-K Item 1 (% — Discontinued After FY2023)
Dữ liệu cập nhật 2026-11-09.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
1. Remaining Performance Obligations (RPO / Backlog) & Contract Balances
2. Sequencing Platform Transition (NovaSeq X) & Organic Revenue Growth Bridge
3. Revenue by Source Matrix (Sequencing vs. Microarray) & Commercial Geography
- Total Disaggregated Revenue by Source ($M) ($M)39 kỳ
- United States and Canada (USCAN) Revenue ($M) ($M)6 kỳ
- Europe, Middle East, Africa and Latin America (EMEALA) Revenue ($M) ($M)6 kỳ
- Greater China Revenue ($M) ($M)39 kỳ
- Asia-Pacific (APAC) Revenue ($M) ($M)6 kỳ
- Unaudited Pro Forma Combined Revenue Including SomaLogic ($M) ($M)8 kỳ
- Americas Revenue (Legacy Structure Through FY2025, $M) ($M)34 kỳ
- Europe Revenue (Legacy Structure Through FY2025, $M) ($M)20 kỳ
- Asia-Pacific, Middle East and Africa (APMEA) Revenue (Legacy Structure Through FY2025, $M) ($M)16 kỳ
4. Operating Expense Disaggregation (ASU 2023-07), Inventories, Warranties & Capital Allocation
- Selling and Marketing Expense ($M) ($M)11 kỳ
- General and Administrative Expense ($M) ($M)11 kỳ
- Total Share-Based Compensation Expense Before Taxes ($M) ($M)43 kỳ
- Total Current Inventories, Net ($M) ($M)43 kỳ
- Reserve for Product Warranties — Ending Balance ($M) ($M)43 kỳ
- Total Government Assistance Grants Receivable ($M) ($M)4 kỳ
- Common Shares Repurchased Under Authorized Programs (Thousand Shares)18 kỳ
- Non-GAAP Gross Profit ($M) ($M)11 kỳ
5. GRAIL, Inc. Standalone Disclosures (Former Consolidated Subsidiary; 14.5% Retained Stake)
6. Workforce, Sustainability, Safety & Executive Compensation (FY2019–FY2025)
- Global Workforce — Total Employees (Employees)7 kỳ
- Total Employee Turnover Rate (%) (%)7 kỳ
- Average Training Hours per Employee per Year (Hours)7 kỳ
- Total Scope 3 Value-Chain Greenhouse Gas Emissions (MT CO2e)7 kỳ
- Total Global Energy Consumption (Gigajoules, GJ)7 kỳ
- Global Total Recordable Injury or Illness Incident Rate (TRIR per 100 FTEs) (×)7 kỳ
- CEO-to-Median-Employee Pay Ratio (x) (×)3 kỳ
7. External Regulatory & Industry Benchmarks (U.S. FDA openFDA & U.S. BLS PPI)
8. Consolidated Financial Statement & Segment Context (GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Illumina
- Illumina Form 10-K for FY2025 (filed 2026-02-12) ↗
- Illumina Form 10-Q for Q3 2026 (filed 2026-10-30) ↗
- Illumina SEC EDGAR XBRL Company Facts (Form 10-K / Form 10-Q) ↗
- Illumina 2025 Corporate Responsibility Report — ESG Performance Data Appendix ↗
- Illumina SEC Form 10-K (Accession 0001110803-26-000024, filed 2026-02-12) ↗
- U.S. FDA openFDA (device/510k.json — Industry IVD 510(k) Clearances) ↗
- U.S. Bureau of Labor Statistics (PPI Series PCU334516334516 — Analytical Laboratory Instrument Manufacturing) ↗
- Illumina SEC Form 10-Q (Accession 0001110803-26-000207, filed 2026-10-30) ↗
- Illumina Form 8-K Q3 2026 Earnings Release (filed 2026-10-29) ↗
- U.S. FDA openFDA (device/pma.json — Illumina PMA Approvals & Supplements) ↗
- Illumina Q3 2026 Earnings Call Transcript (October 29, 2026) ↗
- Illumina Form 8-K Q4 2025 Earnings Release (filed 2026-02-05) ↗
See a number that looks wrong?